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Abstract
Background: An increased risk of breast cancer for relatives of breast cancer patients has been demonstrated
in many studies, and having a relative diagnosed with breast cancer at an early age is an indication for breast cancer
screening. This indication has been derived from estimates based on data from cancer-prone families or from
BRCA1/2 mutation families, and might be biased because BRCA1/2 mutations explain only a small proportion of
the familial clustering of breast cancer. The aim of the current study was to determine the predictive value of a
family history of cancer with regard to early onset of female breast cancer in a population based setting.
Methods: An unselected sample of 1,987 women with and without breast cancer was studied with regard to the
age of diagnosis of breast cancer.
Results: The risk of early-onset breast cancer was increased when there were: (1) at least 2 cases of female
breast cancer in first-degree relatives (yes/no; HR at age 30: 3.09; 95% CI: 128-7.44), (2) at least 2 cases of female
breast cancer in first or second-degree relatives under the age of 50 (yes/no; HR at age 30: 3.36; 95% CI: 1.12–
10.08), (3) at least 1 case of female breast cancer under the age of 40 in a first- or second-degree relative (yes/
no; HR at age 30: 2.06; 95% CI: 0.83–5.12) and (4) any case of bilateral breast cancer (yes/no; HR at age 30: 3.47;
95%: 1.33–9.05). The positive predictive value of having 2 or more of these characteristics was 13% for breast
cancer before the age of 70, 11% for breast cancer before the age of 50, and 1% for breast cancer before the age
of 30.
Conclusion: Applying family history related criteria in an unselected population could result in the screening of
many women who will not develop breast cancer at an early age.
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Breast cancer is the most commonly diagnosed cancer in
women and the second leading cause of cancer death [1].
An increased risk of breast cancer for relatives of breast
cancer patients has been demonstrated in many studies
[2,3]. As physicians and the general population are
becoming more aware of this increased risk, the demand
for referring healthy women with a family history of
breast cancer for intensive screening or genetic testing, is
rising.
In most guidelines the prerequisite for starting breast can-
cer surveillance before the age of 50 is at least one first-
degree relative diagnosed with breast cancer under the age
of 40 [4,5] or 50 [6,7]. Additional criteria are: more than
one relative with breast cancer, relatives with bilateral
breast cancer, ovarian cancer, male breast cancer, or pros-
tate cancer before the age of 60 [8]. These criteria have
been derived from estimates based on data from cancer-
prone families or from BRCA1/2 mutation families. As
BRCA1/2 mutations explain only a small proportion of
the familial clustering of breast cancer [9], estimates based
on these high-risk families may thus have limited value
for the prediction of the age of onset of breast cancer in
the general population. Therefore, empirical data of risks
for family members of unselected cases of breast cancer
are needed to improve current guidelines.
In this study, we used data regarding sisters of recently
diagnosed breast cancer patients. These patients were
unselected for their age at breast cancer diagnosis, and
their family history. The aim of this study was to deter-
mine the predictive value of a family history of cancer
with regard to early onset of female breast cancer in a pop-
ulation-based setting.
Methods
Design
We studied the predictive value of a family history of can-
cer with regard to early onset of breast cancer in a large
group of women with and without breast cancer. These
women were unselected for having breast cancer, but they
all had a family history of breast cancer, having at least
one sister with breast cancer, as they were selected via their
affected sister. These affected sisters (the index patients)
had recently been diagnosed with breast cancer and origi-
nated from a cohort of breast cancer patients who were
unselected for age of breast cancer or family history.
Index patients
Index patients (affected sisters) had a recent diagnosis of
primary invasive breast cancer or DCIS (ductal carcinoma
in situ) and were consecutively asked to participate in a
population-based study "PROSPECT" from 1996 to 2002.
This population-based study was carried out at the Leiden
University Medical Center, Department of Surgery, at the
Diaconessenhuis, Leiden, and at the Erasmus Medical
Center-Daniel den Hoed Cancer Center in Rotterdam,
Departments of Medical Oncology, Radiotherapy and
Surgery. At the Leiden University Medical Center and the
Diaconessenhuis, all patients recently diagnosed with
breast cancer (n = 514) were asked to participate in this
study, irrespective of age. The participation rate was 92%
(n = 471). At the Daniel den Hoed Cancer Center only
patients under the age of 70 were asked to participate. Of
the invited patients, 681 (96.5%) were willing to partici-
pate. From 1996 to July 2002, 1,152 patients participated
and were entered into the database. The Medical Review
Board of the Centers approved the study.
Apart from age of diagnosis, these index patients were
unselected for age of breast cancer diagnosis, family his-
tory for cancer and history of breast cancer screening. The
mean age of the index patients was 52.7 (SD 11.1). Index
patients younger than 70 years in the study were compa-
rable with those registered in the Comprehensive Cancer
Center of The South-West Netherlands during the years
1996–1999, with regard to age distribution (data not
shown). For index patients older than 70 years, our sam-
ple was comprised of few cases when compared to the
almost complete cancer registry of the region. This is
mainly due to the exclusion of these patients in the Daniel
den Hoed Cancer Center. In first-degree relatives of index
patients in our series, the overall breast cancer incidence
was twice as high as in the general population, agreeing
with the excess risk reported in other population-based
studies [2,3]. For 980 index patients, information regard-
ing breast cancer screening history was available. Overall,
632 (64.5%) patients participated in any kind of screen-
ing program. 541 (85.6%) participated in the National
Breast Cancer Screening Program (biannual mammogra-
phy), 42 patients (all above the age of 50; 6.6%) partici-
pated in both the National Breast Cancer Screening
Program and a High Risk Screening Program (annual
mammography), and 49 (7.8%) participated in a High
Risk Screening Program. In the majority of these screened
women, breast cancer was diagnosed based on symptoms
and not based on a finding in the screening program,
namely in 286 (52.7%), 33 (67.3%) and 31 (73.8%)
cases, respectively.
For each index patient the following disease characteris-
tics were recorded: age at diagnosis of first breast cancer,
the occurrence of bilateral breast cancer, and any other
diagnosis of cancer. Based on interviews with the index-
patients, for each index patient a detailed family history of
breast cancer regarding the occurrence of malignancies in
first- and second-degree relatives was assessed, and a ped-
igree was drawn. For each relative, the current age or, if
deceased, age of death was assessed. For each relativePage 2 of 10
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cancer (e.g. breast, ovary, and prostate cancer) was regis-
tered. Medical records of relatives were not checked, so we
were not able to assess types of breast cancer in the family,
or to discern bilateral breast cancer from breast cancer
recurrences in family relatives besides the index patient.
Therefore, the distinction between invasive breast cancer
and DCIS, or unilateral and bilateral breast cancer was
only assessed for the index patients.
Study population
The original cohort contained 1,152 index patients of
whom 286 patients did not have sisters. These patients
and their families could not be included in the study. The
remaining 866 index patients had 1,987 sisters. These
1,987 women with and without breast cancer formed the
study population.
Analyses
We analyzed the impact of a family history of cancer on
the early onset of breast cancer in 1,987 women (sisters).
For each of these women it was determined whether or
not they had been diagnosed with breast cancer and, if so,
at what age. If they were not diagnosed with breast cancer
and still alive, their age at the time of the interview with
the index patient was assessed. If they were not diagnosed
with breast cancer and deceased, their age of death was
assessed. Additionally, their family history was analyzed.
The following were considered to be first-degree relatives
of these women: the affected sister (index patients), moth-
ers, and daughters. To avoid dependency between women
in families with more than one sister, sisters with breast
cancer other than the index patient were excluded from
the family history of the women under study. To explain,
suppose a family with three sisters, in which the index has
a diagnosis of breast cancer as well as one of the other sis-
ters. All sisters, so both a sister affected with breast cancer
and a sister unaffected with breast cancer, were included
in the analysis as an outcome, with only the information
regarding breast cancer in the index patient (the third sis-
ter), mother, daughters and 2nd degree relatives as predic-
tors. The following were considered to be second-degree
relatives: grandmothers, aunts (sisters of mother or
father), and daughters of the affected sister. Early onset of
breast cancer was defined as breast cancer diagnosed
before the age of 50 or breast cancer diagnosed before the
age of 30.
Family histories included the number of cases of breast
cancer in first and second-degree relatives, the age at diag-
nosis of the first breast cancer, ovarian cancer, the combi-
nation of ovarian and breast cancer in one person,
prostate cancer under the age of 60, and bilateral breast
cancer or DCIS in the index patient.
First, we examined the effect of the various family histo-
ries on age at breast cancer diagnosis in the women by
using a Kaplan-Meier model. Log rank tests were per-
formed. Age of the women was taken as time variable. Fol-
low-up time was censored at their age of the diagnosis of
first breast cancer, their age at the moment of the inter-
view with the index patient or the age when dying.
Second, by using Cox-regression, the age of first breast
cancer diagnosis was univariate modeled as a function of
the various types of family histories (covariates) yielding
hazard ratios. Due to low prevalence, the hazard ratios
could be considered as relative risks. To test the assump-
tion of proportional hazards, an interaction term of a cov-
ariate and a time-dependent covariate was added [10]. A
significant effect of that interaction term denotes the pres-
ence of a time-dependent effect and thus a violation of the
proportional hazards assumption. As the estimated haz-
ard ratios were not constant over time, we performed Cox-
regression with a time-dependent effect, with age at breast
cancer diagnosis in the women under study as the
dependent variable. For each covariate, a model was built
including this covariate and an interaction term of a cov-
ariate and a time-dependent covariate. Hazard ratios for
the women's chances of developing breast cancer at age 30
and an estimate of the relative change with increasing age
(a period of 10 years) of these hazard ratios were calcu-
lated.
Then, a multivariate analysis was performed, by using a
Cox-regression model again with a time-dependent effect,
and with age at breast cancer diagnosis in the women
under study as the dependent variable. The model was
built in a stepwise fashion, including variables that
improved the overall fit of the model with statistical sig-
nificance (p < 0.05). Again, a hazard ratio for the women's
chances of developing breast cancer at age 30 and an esti-
mate of the relative change with increasing age (a period
of 10 years) of this hazard ratio was calculated.
The developed model was used to calculate a model score,
based on the family history characteristics included in the
multivariate model. Each family history characteristic
yielded one point in this model. Then we verified how
many women with breast cancer were identified correctly,
by using different cut-off values of the model score. Fur-
thermore, positive and negative predictive values of the
model, with regard to an early onset of breast cancer in the
women under study, were calculated.
Results
Study population
Of the 1,987 women under study, 136 (6.8%) had been
diagnosed with breast cancer. The incidence of breast can-
cer increased with age (Figure 1).Page 3 of 10
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The 1,987 women included in the study had 32,791 first
or second-degree relatives in total. A higher risk of breast
cancer among these women was statistically significantly
related to having at least 2 cases of female breast cancer in
first or second-degree relatives, at least 1 case of early
female breast cancer (i.e. under the age of 50 or 40), or
bilateral breast cancer (Table 1). These effects were
stronger for women under the age of 50 with breast can-
cer. The presence of one of these characteristics more than
doubled the breast cancer risk at age 30 (Table 2). This risk
decreased with increasing age.
In this population, having at least 2 cases of female breast
cancer under the age of 40, having at least 1 case of female
breast cancer under the age of 30, or having male breast
cancer or prostate cancer under the age of 60 was rare
(Table 1). Ovarian cancer and DCIS were not statistically
significant associated with an early age at onset of breast
cancer in the women under study (Table 1).
Four variables (at least 2 cases of female breast cancer in
first-degree relatives (yes/no), at least 2 cases of breast can-
cer in first or second-degree relatives under the age of 50
(yes/no), at least 1 case of breast cancer under the age of
Age at onset of first breast cancer among the women under studyFigure 1
Age at onset of first breast cancer among the women under study. x-axis: Age at first breast cancer. y-axis: Cumula-
tive incidence.
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case of bilateral breast cancer (yes/no)) contributed to the
presence of breast cancer at 30 years of age, both inde-
pendently and with statistical significance (Table 3). Of
these four family characteristics, the highest hazard ratio
for developing breast cancer was related to bilateral breast
cancer (HR: 3.47) and the lowest was related to having at
least one case of female breast cancer under the age of 40
(HR: 2.06). All the hazard ratios decreased with increasing
age, except the one related to having at least one case of
female breast cancer under the age of 40 years.
Model score
Based on family history characteristics included in the
multivariate model, a model score was calculated; each
family history characteristic yielded one point in this
model. As scores of three and four were rare (seven and
three cases respectively), the score was recoded into '0', '1',
and '2 or more'. Scores of 1 and higher were registered for
about one-quarter of all (affected and disease-free)
women, for about one-third of the women with breast
cancer (regardless of age), for 40% of the women with
breast cancer under the age of 50, and for 60% of the
women with breast cancer under the age of 30 (Table 4).
Predictive value of model score
As the model score increased, the age of breast cancer
diagnosis decreased (Figure 2). The hazard ratio for devel-
oping breast cancer at 30 years of age was notably related
to a model score of 2 or more (10.62; Table 3). With
increasing age of the women, this hazard decreased
sharply (hazard ratio at age 40: 4.56; at age 50: 1.96).
The positive predictive values for model scores of '1 or
more' and '2 or more' for breast cancer before the age of
30 were 0,5% and 0.9% respectively, 4% and 11% respec-
tively for breast cancer before the age of 50, and 8% and
13% respectively for breast cancer before the age of 70
Table 1: Family histories* of all women under study (N = 1,987), of all women with breast cancer (n = 136) and of all women with 
breast cancer under the age of 50 (n = 73)
Presence of Family characteristics All women Women with breast cancer
Breast cancer 
at any age
Log rank; P Breast cancer 
under age 50
Log rank; P
N (%) N (%) N (%)
Total 1987 (100) 136 (6.8) 73 (3.7)
≥ 2 cases of female breast cancer in first or second-degree 
relatives
614 (30.9) 54 (39.7) 7.39; P = .007 31 (5.0) 5.02; P = .03
≥ 2 cases of female breast cancer in first-degree relatives 165 (8.3) 20 (14.7) 5.23; P = .02 13 (17.8) 9.85; P = .002
≥ 1 case of female breast cancer under age 50 789 (39.7) 52 (6.6) 12.47; P = .0004 35 (4.4) 7.85; P = .005
≥ 2 cases of female breast cancer under age 50 113 (5.7) 10 (8.8) 1.92; P = .17 10 (8.8) 12.33; P = .0004
≥ 1 case of female breast cancer under age 40 231 (11.6) 18 (7.8) 12.01; P = .0005 12 (5.2) 8.52; P = .004
≥ 2 cases of female breast cancer under age 40 10 (0.5) - - - -
≥ 1 case of female breast cancer under age 30 33 (1.7) 1 (3.0) - 1 (3.0) -
Male breast cancer 12 (0.6) 1 (8.0) - 1 (8.0) -
Bilateral breast cancer in affected sister (index patient) 104 (5.2) 16 (15.4) 13.94; P = .0002 11 (10.6%) 15.00; P = .0001
Ovarian cancer 54 (2.7) 5 (9.3) 1.93; P = .16 3 (5.5%) 1.23; P = .27
Breast and ovarian cancer in one person 8 (0.4) 2 (25.0) 12.05; P = .0005 2 (25%) 14.00; P = .0002
Prostate cancer under age 60 43 (2.1) 1 (2.3) 1 (2.3%)
DCIS in affected sister (index patient) 169 (8.5) 15 (8.9) 0.97; P = .32 7 (4.1%) 0.04; P = .84
* To avoid dependency between women in families with more than one sister, sisters other than the index patient were excluded from the family 
history of the women under study.Page 5 of 10
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scores varied from nearly 100% to 94%. The concordance
index varied from 77% tot 94%.
Discussion and Conclusion
The aim of this study was to examine whether a family his-
tory of cancer is useful in predicting early-onset female
breast cancer. This was studied in a population-based set-
ting as compared to a high-risk clinic. Family history was
indeed a strong indicator of an early diagnosis of breast
cancer, and it was most strongly related to breast cancer
diagnosed before the age of 50. Factors related to family
histories that were connected to a younger age at breast
cancer diagnosis were: (1) at least 2 cases of female breast
cancer in first-degree relatives (yes/no), (2) at least 2 cases
of female breast cancer in first or second-degree relatives
under the age of 50 (yes/no), (3) at least 1 case of breast
cancer in a woman younger than 40 years in a first or sec-
ond-degree relative (yes/no), and (4) any case of bilateral
breast cancer (yes/no). These four factors were included in
a model score, each representing one point in this model.
When at least two of these characteristics were present, we
Table 2: The effect of the various patterns of breast cancer in the family on the age of onset of breast cancer in the women under study 
(univariate) *
Family characteristics Relative risk at 
age 30**
95% C.I. 
relative risk at
of  age 30
Change of  
relative risk per
10 years ***
Overall  
Significance
****
≥ 2 cases of female breast cancer in first or second-degree relatives (yes vs. no) 2.20 1.15–4.22 0.851 P = .013
≥ 2 cases of female breast cancer in first-degree relatives (yes vs. no) 4.28 1.89–9.70 0.624 P = .001
≥ 1 case of female breast cancer under age 50 (yes vs. no) 2.82 1.43–5.57 0.800 P = .001
≥ 2 cases of female breast cancer under age 50 (yes vs. no) 5.81 2.16–15.60 0.825 P = .002
≥ 1 case of female breast cancer under age 40 (yes vs. no) 3.21 1.36–7.56 0.825 P = .001
Bilateral breast cancer in affected sister (index patient) (yes vs. no) 4.00 1.55–10.32 0.784 P = .000
Ovarian cancer (yes vs. no) 2.72 0.58–12.83 0.801 P = .294
DCIS in affected sister (index patient) (yes vs. no) 0.89 0.30–2.63 1.184 P = .412
* Due to small numbers, results regarding ≥ 2 cases under age 40 and ≥ 1 or 2 case under age 30 of female breast cancer, male breast cancer, breast 
and ovarian cancer in one person and prostate cancer under age 60 are not presented.
** Due to low prevalence, the hazard ratio can be considered as a relative risk.
*** The relative risk at age 30 can be multiplied with this factor for calculating the relative risk at age 40, age 50 and so on.
**** Model significance was based on the likelihood ratio of the final model as compared to the O-model without any covariate.
Table 3: The effect of the various patterns of breast cancer in the family on the age of onset of breast cancer in the women under study 
(multivariate)
Family characteristics Relative risk at 
age 30 *
95% C.I. of  
relative risk at
age 30
Change of 
relative risk per 
10 years **
Overall
Significance
***
≥ 2 cases of female breast cancer in first or second-degree relatives (yes vs. no) 3.09 1.28–7.44 0.745
≥ 2 cases of female breast cancer under age 50 (yes vs. no) 3.36 1.12–10.08 0.489
≥ 1 case of female breast cancer under age 40 (yes vs. no) 2.06 0.83–5.12 1.000
Bilateral breast cancer in affected sister (index patient) (yes vs. no) 3.47 1.33–9.05 0.834 < .001
Model score ****
0 ***** 1
1 2.01 (0.89–4.55) 0.942
≥ 2 10.62 (4.22–26.72) 0.430 <.001
* Due to low prevalence, the hazard ratio can be considered as a relative risk.
** The relative risk at age 30 can be multiplied with this factor for calculating the relative risk at age 40, age 50 and so on.
*** Model significance was based on the likelihood ratio of the final model as compared to the O-model without any covariate.
**** Model score based on the family characteristics included in the multivariate model, each characteristic present yields one point.
***** Reference category.Page 6 of 10
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age of 30 of 10.62. With increasing age, this hazard
decreased sharply (hazard ratio at age 40: 4.56; at age 50:
1.96). However, due to the low prevalence of early breast
cancer in the population, the positive predictive value of
the presence of at least 2 of the 4 characteristics (a model
score of 2 or more) was 13% for breast cancer before the
age of 70, 11% for breast cancer before the age of 50, and
Table 4: The model scores
Model score Number of selected 
women
Women with breast 
cancer
Women with breast 
cancer under age 50
Women with breast 
cancer under age 30
0 1496 (75.3%) 91 (66.9%) 44 (60.3%) 2 (40%)
1 382 (19.2%) 31 (22.8%) 17 (23.3%) 2 (40%)
≥ 2 109 (5.5%) 14 (10.3%) 12 (16.4%) 1 (20%)
Age at onset of first breast cancer among the women under study related to the model scoreFigure 2
Age at onset of first breast cancer among the women under study related to the model score. x-axis: Age at 
onset of first breast cancer. y-axis: Cumulative incidence
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predictive value was respectively, 94%, 97% and nearly
100%.
In most guidelines the prerequisite for starting breast can-
cer surveillance before the age of 50 is at least one first-
degree relative diagnosed with breast cancer under the age
of 40 [4,5] or 50 [6,7]. Additional criteria are: more than
one relative with breast cancer, relatives with bilateral
breast cancer, ovarian cancer, male breast cancer, or pros-
tate cancer before the age of 60 [8]. In our study, at least 2
cases of female breast cancer in first-degree relatives, or
having at least 1 case of breast cancer in a woman younger
than 40 years in a first or second-degree relative were asso-
ciated with early onset of breast cancer. This is in line with
Claus tables who models age of onset of breast cancer as a
function of family history of breast among first degree rel-
atives [11]. As compared to the Claus tables, we added the
criterion having at least 2 cases of female breast cancer in
first or second-degree relatives under the age of 50. In our
study, having one first-degree relative with breast cancer
before the age of 50 was not associated with early onset
breast cancer. This is also in line with the Claus tables
[11].
In our study, male breast cancer, DCIS, ovarian cancer,
and prostate cancer under age 60 in the family were not
associated with early onset of breast cancer. In addition,
we found a lower prevalence of ovarian cancer, early onset
prostate cancer and male breast cancer than in other stud-
ies on breast cancer risk assessment [12-14]. A first expla-
nation might be that these types of cancer are not very well
known among family members and that these cancers
may be underreported in the original interviews with the
index patient, with regard to the family history of cancer.
All data regarding family history were based on interviews
with the index patients; medical records of relatives with
malignancy were not checked. This can be considered a
valid method insofar as family history is limited to breast
cancer among first-degree relatives [15]. Data regarding
ovarian and prostate cancer and data regarding second-
degree relatives might be underreported [16]. As a conse-
quence, our study had not enough power to analyze
whether presence of male breast cancer or ovarian cancer
is useful in predicting early-onset female breast cancer.
A second explanation might be, that these types of cancer
are more frequent in the study populations of mentioned
studies, than could be expected in the general population,
as these studies focused on the prediction of breast cancer
risk using estimates on the prevalence and penetrance of
BRCA1 and BRCA2 mutations. As ovarian cancer, early
onset prostate cancer and male breast cancer are associ-
ated with such mutations [17,18], the study populations
of these studies may have included high risk groups more
frequently than low risk groups.
Bilateral breast cancer is generally considered an indicator
of a genetic susceptibility of breast cancer. However,
recent studies showed only a weak association of BRCA1/
2 mutation status with bilateral breast cancer [19-21]. In
our study bilateral breast cancer is strongly related to early
onset of breast cancer. This may indicate that genes other
than BRCA1 and BRCA2 are involved in familial cluster-
ing of bilateral breast cancer.
We based our analyses on the presence or absence of
breast cancer in women who were sisters of breast cancer
patients. These breast cancer patients were included as
index patients in a cohort study. Apart from age of diagno-
sis, this series of index patients can be considered repre-
sentative of women with a diagnosis for breast cancer,
unselected for family history of breast cancer. In one of
the participating centers, only patients under the age of 70
were asked to participate. This selection on age might give
a slight overestimation of the risks found in this study,
especially for the older age groups. Due to relatively small
number of index cases in the age group of 70 years and
over, we were not able to quantify these effects. However,
as the prediction of female early onset breast cancer based
on a family history of breast cancer will be especially
important for younger women, we suppose that the effects
are marginal.
91 (9%) affected patients participated in a High Risk
Screening Program with annual mammography. Among
these women, only one-third of the breast cancers (n = 27)
was diagnosed based on a finding in the screening pro-
gram. We expect that part of the sisters of these affected
Table 5: The positive and negative predictive value of the model 
scores and the concordance index
Model 
score
Positive predictive 
value
Negative predictive 
value
Concordance 
index*
Outcome: Woman with breast cancer under age 70
1 8.1% 93.9% 77.4%
≥ 2 12.8% 93.9% 89.4%
Outcome: Woman with breast cancer under age 50
1 4.4% 96.5% 78.8%
≥ 2 11.0% 96.8% 92.0%
Outcome: Woman with breast cancer under age 30
1 0.5% 99.8% 80.7%
≥ 2 0.9% 99.8% 94.4%
* Percentage of correctly classified cases.Page 8 of 10
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Program before their sister (the index patient of our study)
was diagnosed with breast cancer. Because it is a very
small group we do not expect this has influenced the out-
comes of the here presented analysis.
In theory, there might be cohort effects regarding the age
of onset of breast cancer. We checked the data, but could
not find any. As a consequence, there was no indication to
control for a cohort effect. Another consequence was that
we could consider the outcome (a sister's cancer) as an
equivalent to the predictor (the index cancer) and mutual
exchangeable, which allowed us to perform the analysis
we did.
Including population-based control subjects who did not
have a sister with breast cancer would have given us the
opportunity to estimate a baseline risk for women with-
out a family history of breast cancer. However, early-onset
breast cancer incidence in the absence of any family his-
tory for cancer is likely to be quite low, and because it was
not related to the main question of this analysis, we
decided not to perform such a study.
Ideally, the current study should be carried out in families
who test negative for BRCA1/2 and other familial breast
cancer genes. On the other hand, the two breast cancer
susceptibility genes thus far known, BRCA1 and BRCA2,
only explain 15–20% of the familial clustering of breast
cancer, and less than 5% of breast cancer overall [9]. As a
consequence, for most women with a family history of
cancer, their breast cancer risk estimate will be based on
their family history and not on their genetic status [22].
Correction for possible bias, due to dependency between
women in families with more than one sister, has not
been part of this analysis, as sisters other than the index
patient were excluded from the family history of the
women under study. Supposing there is some depend-
ency, the accuracy (width of the confidence intervals) of
the data might be slightly overestimated. However,
because the significance levels are far from the 5% level,
we do not expect that this has had an influence on our
results.
Validating this model is a next step of research and should
preferably be performed in another database [23].
Another way of validating this model is to compare it with
existing models. However, as mentioned in the introduc-
tion, most existing models have been derived from esti-
mates based on data from cancer prone families. The aim
of the current study was to work on a model based on a
population not selected for family history of (breast) can-
cer. The most known model based on such a population
is the Claus model, which predictions are in line with our
results. Though not demonstrated in this study, it has
been shown that male breast cancer and ovarian cancer
are important covariates in predicting early onset breast
cancer [24,25]. Further research is needed to assess the
predictive value of DCIS and prostate cancer under the age
of 60.
In conclusion: applying family history related criteria
could result in the screening of many women who will not
develop breast cancer at an early age. Chances of develop-
ing early breast cancer are very small, when there is lim-
ited family history for (breast) cancer and none or only
one of the following criteria is applicable: (1) at least 2
cases of female breast cancer in first-degree relatives; (2) at
least 2 cases of female breast cancer in first or second-
degree relatives under the age of 50; (3) at least 1 case of
female breast cancer under the age of 40 in a first- or sec-
ond-degree relative; and (4) any case of bilateral breast
cancer. If the model score of women would be below 2
points, their risk for developing breast cancer at an early
age would be low, and screening at an early age might not
be indicated. At age 40 or 50 (depending on the country
they live in), these women will be invited to participate in
the national screening program. If the model would be
used in clinical decision settings, it would be an easy to
use method to reassure a large number of women regard-
ing their personal breast cancer risk at an early age and
their need to be referred to early screening programs or
genetic centers.
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